Durgical
EN
Open the app

Clotting tests: which one answers which question

  • Reading the test

Each clotting test looks at one stretch of the clotting chain. Knowing which stretch stops you ordering the wrong test or trusting a normal one.

Updated

What it is

The routine clotting screen is the platelet count, the prothrombin time (PT, reported as the INR), the activated partial thromboplastin time (aPTT) and fibrinogen. The PT measures factor VII and the common pathway (X, V, II, fibrinogen); the aPTT measures factors XII, XI, IX and VIII and the same common pathway. The thrombin time looks only at the last step, fibrinogen becoming fibrin. Second-line tests answer narrower questions: the mixing study (missing factor or inhibitor?), single factor levels, anti-Xa activity (how much heparin or Xa inhibitor is on board), von Willebrand studies, platelet function tests, D-dimer and viscoelastic tests at the bedside.

What it measures and the numbers that matter

  • PT/INR: factor VII plus the common pathway; the INR was built to compare warfarin results between laboratories, not to grade liver disease or DOAC effect.
  • aPTT: factors XII, XI, IX, VIII plus the common pathway; used for unfractionated heparin and to screen for haemophilia and lupus anticoagulant.
  • Thrombin time: prolonged by heparin, dabigatran, low or abnormal fibrinogen and fibrin breakdown products; a normal thrombin time makes a meaningful dabigatran level unlikely.
  • Fibrinogen: falls in DIC, massive bleeding and severe liver disease; it is an acute-phase protein, so a 'normal' value can hide a fall in sepsis or pregnancy.
  • Anti-Xa activity measures heparin, low-molecular-weight heparin or, with drug-specific calibration, a Xa inhibitor.
  • Blind spots: PT and aPTT are normal in platelet disorders, most von Willebrand disease, factor XIII deficiency and vessel disorders.

How to read it, in order

  1. Check the sample first: an underfilled citrate tube, a very high haematocrit, a clot or blood drawn from a heparinised line all distort results.
  2. Read the platelet count and the smear before the clotting times.
  3. Read PT and aPTT together and place them on the grid (PT alone, aPTT alone, both, neither).
  4. Add fibrinogen and D-dimer: low fibrinogen with high D-dimer points to consumption (DIC) or massive bleeding.
  5. Ask what drug is on board and when it was last taken before reading any prolonged time.
  6. Prolonged time without a drug: mixing study. Corrects = missing factor (measure it); does not correct = inhibitor (lupus anticoagulant or factor antibody).
  7. Normal screen with a real bleeding history: von Willebrand studies, platelet function and factor XIII.

Which test answers which question

TestMeasuresProlonged or abnormal inMisses
PT/INRFactor VII and the common pathwayWarfarin, vitamin K deficiency, liver disease, DIC, some Xa inhibitorsHaemophilia, heparin at usual levels, platelets, VWD
aPTTFactors XII, XI, IX, VIII and the common pathwayHeparin, haemophilia A and B, factor XI deficiency, lupus anticoagulant, some VWD, dabigatranFactor VII deficiency, platelets, factor XIII
Thrombin timeFibrinogen to fibrinHeparin, dabigatran, low or abnormal fibrinogen, breakdown productsEverything upstream of thrombin
Anti-XaDrug activity against factor XaHeparins; Xa inhibitors with a calibrated assayWarfarin, dabigatran
Mixing studyMissing factor versus inhibitorCorrects: deficiency; does not correct: inhibitorNormal screens (nothing to mix)

Reading errors

  • A falsely long PT and aPTT from an underfilled tube or a haematocrit above about 55% is a classic laboratory artefact; repeat with a correct sample.
  • Blood from a line flushed with heparin prolongs the aPTT and thrombin time; redraw from a clean venepuncture.
  • A normal PT and aPTT do not exclude a Xa inhibitor at a level that matters, particularly apixaban.
  • A long aPTT that does not correct on mixing in a patient with clots is lupus anticoagulant; in a patient with sudden large bruises it may be acquired haemophilia.

Next step

  • Before surgery or a procedure, screen only when the bleeding history or the drug list suggests a problem; a structured bleeding history predicts better than routine tests.
  • Isolated long aPTT: mixing study, then factors VIII, IX, XI and lupus anticoagulant.
  • Patient on a DOAC who needs urgent surgery or is bleeding: ask the laboratory for a drug-specific level (calibrated anti-Xa, or dilute thrombin time for dabigatran).
  • Massive bleeding: repeat count, PT, aPTT and fibrinogen often, or use bedside viscoelastic tests where available, to guide components.
  • Normal screen with a strong history: send to a haemostasis laboratory for von Willebrand, platelet function and factor XIII tests.

Common traps

  • Reading the INR as a measure of bleeding risk in liver disease: it was standardised for warfarin and does not capture the balanced loss of pro- and anticoagulant proteins.
  • Taking a normal PT and aPTT as proof that no DOAC is present: sensitivity varies by drug and reagent.
  • Assuming a long aPTT means bleeding: lupus anticoagulant and factor XII deficiency prolong it without bleeding.
  • Ordering the obsolete bleeding time: it is poorly reproducible and has been replaced by specific platelet tests.

Test yourself

Think of the answer, then tap the question to see it.

Why is the PT prolonged but the aPTT normal in early warfarin therapy or early vitamin K deficiency?

Factor VII has the shortest half-life of the vitamin K-dependent factors and is measured only by the PT, so it falls first; IX, X and II fall later.

A well patient has a long PT and aPTT on a sample with a haematocrit of 62%. What should be done next?

Repeat with a citrate volume adjusted for the haematocrit: the small plasma volume leaves too much citrate, which falsely prolongs both times.

Which single test best tells whether a bleeding patient has a meaningful amount of dabigatran on board?

A thrombin time: a normal result makes a meaningful level unlikely; a dilute thrombin time or calibrated assay gives the amount.

A long aPTT does not correct with normal plasma. What are the two main explanations, and how do they differ clinically?

Lupus anticoagulant, which causes clots, and a factor antibody such as acquired haemophilia A, which causes serious bleeding.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Interpretation of Blood Clotting Studies and Values (PT, PTT, aPTT, INR, Anti-Factor Xa, D-Dimer) (StatPearls (NCBI Bookshelf), 2025); Prothrombin Time (StatPearls (NCBI Bookshelf), 2026); Partial Thromboplastin Time (StatPearls (NCBI Bookshelf), 2023); Prothrombin Time Test and INR (PT/INR): MedlinePlus Medical Test (MedlinePlus, US National Library of Medicine, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.